Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 11 - 20 of 333

<< Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next >>

Last updated: 20th February 2008

Patent No.: WO 081486
Oral administration of defensins to treat intestinal diseases.
Applicant: Wehkamp J, Huang N, Bevins CL, Stange E (2007)
The present invention relates to oral administration of defensins for the treatment of intestinal diseases such as ulcerative colitis and Crohn's disease. The defensins are preferably human defensins, and are more preferably human alpha-defensins and beta-defensins. The defensins may be provided in a dosage form that is suitable for oral administration to a patient suffering from intestinal disease.

Patent No.: WO 077257
Acne lesions biomarkers and modulators thereof.
Applicant: Thiboutot D (2007)
The present invention relates to acne lesions biomarkers/ genes expression products pattern and particularly inflammatory acne lesions biomarkers and their uses, modulators thereof and the use of modulators for acne treatment or associated disorders. Invention also concerns in vitro diagnostic methods. Gene array expression profiling reveiled a prominent role of matrix metalloproteinases, inflammatory cytokines anti-microbial peptides in acne lesions. The increased expression of human beta-defensins in acne lesions was confirmed by quantitative PCR.

Patent No.: WO 065128
Human alpha-defensins inhibit interleukin-1beta release.
Applicant: Shi J, Aono S, Lu W (2007)
Human alpha-defensins are inhibitors of interleukin-1beta post transitional processing and release. Interleukin-1beta is a key cytokine involved in the initiation and amplification of the 5 inflammatory process, including the inflammation of diseases such as Crohn's Disease and Ulcerative Colitis. Particularly, human neutrophil defensin-1 (HNP-1) produced mainly by neutrophils, and human alpha-defensin 5(HD-5) produced by Paneth cells has been found to block interleukin-1beta post transitional processing and release. Thus, a pharmaceutical compn. and method for treating inflammation in the mammalian tissues is herein disclosed. The pharmaceutical compn. is a therapeutic supplementation of a metabolic pathway to reduce inflammation comprising a human alpha-defensins in a therapeutically effective amt. or an amide, ester or salt thereof and a pharmaceutically effective carrier. The method for treating inflammation in mammalian tissues includes administering a human alpha-defensins to a mammal in an amt. effective to inhibit the post translational processing and release of interleukin-1beta.

Patent No.: WO 047512
Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy.
Applicant: Donald CD (2007)
Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX 2 can be by administration of a nucleic acid encoding an siRNA for PAX 2. Dharmachon is a com. source for such siRNAs. A method of treating cancer in a subject by administering DEFB1 (human beta defensin 1) is also provided. An example of a cancer treated by the present method is prostate cancer. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. In the method wherein the expression of DEFB1 is increased, it can be increased by blocking the binding of PAX2 to the DEFB1 promoter. The blocking of binding of PAX2 to the DEFB1 promoter can be by administration of an oligonucleotide contg. the PAX2 DNA binding site of DEFB1. This oligonucleotide can be complementary to the sequence of PAX2 that binds to the DEFB1 promoter. Alternatively, the oligonucleotide can interact with the PAX2 in a way that inhibits binding to DEFB1. This interaction can be based on three-dimensional structure rather than primary nucleotide sequence.

Patent No.: WO 044998
Retrocyclins: antiviral and antimicrobial peptides.
Applicant: Lehrer RI, Waring AJ, Bradley KA, Wang W (2007)
Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical compn. comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from an infection by a vancomycin resistant enterococcus.

Patent No.: WO 038623
Oral formulation comprising milk protein for treatment of enteric disorder.
Applicant: Hagie FE, Bethell D, Huang N (2007)
The present invention relates, generally, to oral formulations including one or more recombinantly-produced human milk proteins. The formulations of the present invention may be used to prevent the onset of diarrhea in patients who have been or will be exposed to one or more agents known to cause diarrhea, and to prevent the recurrence of diarrhea in a patient recovering therefrom. The formulations may also be used in the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. The formulations may also be beneficially administered in accordance with methods for promoting the development of healthy intestinal flora in a human patient.

Patent No.: WO 025333
Use of transgenic derivatives of poultry gut Gram-negative bacteria as probiotics.
Applicant: Moore RJ, Rood JI, Sheedy SA (2007)
Methods for the delivery of biol. active polypeptides to a subject by colonizing the gut with non-pathogenic Gram neg. bacteria carrying the gene for the polypeptide are described. Also provided by this invention are methods of treating or preventing diseases by administering colonizing Gram neg. bacteria that express one or more biol. active polypeptides. The antimicrobial peptide tested was a bacteriocin called Piscicolin 126. The colonizing non-pathogenic Gram neg. bacteria may be administered in pharmaceutical formulations. The preferred targets for this treatment are poultry and the preferred transgenic bacterium is a strain of Escherichia coli H10 or Salmonella sofia. The bacteria may be labeled for surveillance with marker genes such as a reporter gene or an antibiotic resistance marker. Suitable bacteria were identified by screening for persistence in specific pathogen-free poultry. Candidate strains of E. coli were then tested for their ability to maintain a transgene.

Patent No.: WO 025178
Pharmaceutical compositions comprising antimicrobial or antiviral polypeptides conjugated with biocompatible polymers for treating microbial or viral infection.
Applicant: Malamud D, Abrams W, Arora P, Liu Z, Kallenbach N (2007)
The invention is directed to compns. comprising polyvalent complexes contg. a biocompatible polymer backbone to which is attached a plurality of monomeric anti-microbial peptides and to methods for using such complexes to stabilize anti-microbial peptides for treating or preventing a disease or condition resulting from infection with a microbe. The peptide is selected from antiviral protein Y3, Alloferon 1, Lactoferricin B, hexapeptide, Tricyclic peptide RP, indolicidin, GNCP-1, GNCP-2, HNP-1 defensin, HNP-2 defensin, HNP-3 defensin, corticostatin III, corticostatin IV, NP-3A defensin, protegrin 2, protegrin 3, protegrin 4, protegrin 5, RatNP-1, RatNP-2, RatNP-3, RatNP-4, caerin 1.1, circulin A, circulin B, cyclopsychotride A, ginkobilobin, alpha-basrubrin and salivary agglutinin protein. Multivalent derivs. of existing antimicrobial peptides in which several peptides are covalently linked have been investigated. The resulting construct may contain up to 30 or more units, and exhibits a significant enhancement of anti-microbial effect relative to the free peptides: on the order of a ten fold improvement in effectiveness, suggesting that higher multimerization can indeed lead to more effective agents. The invention is also directed to the use of such complexes for delivery of anti-viral peptides, in particular, peptides and peptide fragments obtained from salivary agglutinin protein (gp-340 ) for use in treating or preventing infection with HTV.

Patent No.: WO 022254
Pharmaceutical formulations for sustained drug delivery.
Applicant: Gefter ML, Barker N, Musso GF, Molineaux CJ (2007)
Sustained delivery formulations comprising a water-insol. complex of a peptidic compd. (e.g., a peptide, polypeptide, protein, peptidomimetic or the like) and a carrier macromol. are disclosed. The formulations of the invention allow for loading of high concns. of peptidic compd. in a small vol. and for delivery of a pharmaceutically active peptidic compd. for prolonged periods, e.g. , one month, after administration of the complex. The complexes of the invention can be milled or crushed to a fine powder. In powd. form, the complexes form stable aq. suspensions and dispersions, suitable for injection.

Patent No.: WO 020884
Bifidobacterium or lactic acid bacterium having effect of preventing infection via beta-defensin and food/pharmaceutical composition containing the same.
Applicant: Shibata T, Terahara M, Yajima M (2007)
It is intended to provide a Bifidobacterium or lactic acid bacterium having an effect of preventing infection by increasing the expression level of beta-defensin. By sensitizing an animal cell to this in advance or simultaneously, the expression level of beta-defensin can be dramatically increased upon infection with a large amount of a pathogenic bacterium such as E. coli. Further, it is intended to provide a food/pharmaceutical composition containing the Bifidobacterium and/or lactic acid bacterium as an active ingredient and having the effect of preventing infection by increasing the expression level of beta-defensin.